Aralkylamine N-acetyltransferase

Last updated
Aralkylamine N-acetyltransferase
SNAT PDB-code 1KUX.png
Crystallographic structure of aralkylamine N-acetyltransferase. [1]
Identifiers
EC no. 2.3.1.87
CAS no. 92941-56-5
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / QuickGO
Search
PMC articles
PubMed articles
NCBI proteins
Aralkylamine N-acetyltransferase
Identifiers
SymbolAANAT
NCBI gene 15
HGNC 19
OMIM 600950
RefSeq NM_001088
UniProt Q16613
Other data
EC number 2.3.1.87
Locus Chr. 17 q25
Search for
Structures Swiss-model
Domains InterPro

Aralkylamine N-acetyltransferase (AANAT) (EC 2.3.1.87), also known as arylalkylamine N-acetyltransferase or serotonin N-acetyltransferase (SNAT), is an enzyme that is involved in the day/night rhythmic production of melatonin, by modification of serotonin. It is in humans encoded by the ~2.5 kb AANAT gene [2] containing four exons, located on chromosome 17q25. [3] The gene is translated into a 23 kDa large enzyme. It is well conserved through evolution and the human form of the protein is 80 percent identical to sheep and rat AANAT. It is an acetyl-CoA-dependent enzyme of the GCN5-related family of N-acetyltransferases (GNATs). It may contribute to multifactorial genetic diseases such as altered behavior in sleep/wake cycle [2] and research is on-going with the aim of developing drugs that regulate AANAT function.

Contents

Nomenclature

The systematic name of this enzyme class is acetyl-CoA:2-arylethylamine N-acetyltransferase. Other names in common use include:

The officially accepted name is aralkylamine N-acetyltransferase. [4]

Function and mechanism

Tissue distribution

The AANAT mRNA transcript is mainly expressed in the central nervous system (CNS). It is detectable at low levels in several brain regions including the pituitary gland as well as in the retina. It is most highly abundant in the pineal gland which is the site of melatonin synthesis. Brain and pituitary AANAT may be involved in the modulation of serotonin-dependent aspects of human behavior and pituitary function. [3]

Physiological function

In the pinealocyte cells of the pineal gland, aralkylamine N-acetyltransferase is involved in the conversion of serotonin to melatonin. It is the penultimate enzyme in the melatonin synthesis controlling the night/day rhythm in melatonin production in the vertebrate pineal gland. Melatonin is essential for seasonal reproduction, modulates the function of the circadian clock in the suprachiasmatic nucleus, and influences activity and sleep. Due to its important role in circadian rhythm, AANAT is subjected to extensive regulation that is responsive to light exposure (see Regulation). It may contribute to multifactorial genetic diseases such as altered behavior in sleep/wake cycle and mood disorders. [2]

The chemical reactions catalyzed by AANAT

The primary chemical reaction that is catalyzed by aralkylamine N-acetyltransferase uses two substrates, acetyl-CoA and serotonin. AANAT catalyzes the transfer of the acetyl group of Acetyl-CoA to the primary amine of serotonin, thereby producing CoA and N-acetylserotonin. In humans, other endogenous substrates of the enzyme include specific trace amine neuromodulators, namely phenethylamine, tyramine, and tryptamine, in turn forming N-acetylphenethylamine, N-acetyltyramine, and N-acetyltryptamine. [5]

Synthesis of Melatonin from Serotonin through two enzymatic steps.png

In the biosynthesis of melatonin, N-acetylserotonin is further methylated by another enzyme, N-acetylserotonin O-methyltransferase (ASMT) to generate melatonin. The N-acetyltransferase reaction has been suggested to be the rate-determining step, and thus Serotonin N-acetyltransferase has emerged as a target for inhibitor design (see below). [6]

AANAT obeys an ordered ternary-complex mechanism. The substrates bind sequentially (ordered) with acetyl-CoA binding to the free enzyme followed by the binding of serotonin to form the ternary complex. After the transfer of the acetyl group has occurred, the products are orderly released with N-acetyl-serotonin first and CoA last. [7]

Structure

Arylkylamine N-acetyltransferase is a monomeric polypeptide with a length of 207 amino acid residues, and with a molecular weight of 23,344 daltons. The secondary structure consists of alpha helices and beta sheets. It is 28 percent helical (10 helices; 60 residues) and 23 percent beta sheet (9 strands; 48 residues). This family shares four conserved sequence motifs designated A-D. Motif B serves as the location of the serotonin binding slot. The structure was determined by X-ray diffraction. [1]

Several structures have been solved for this class of enzymes, with PDB accession codes 1CJW ​, [8] 1B6B ​, [9] 1L0C ​, [1] [10] and 1KUV ​/ 1KUX ​/ 1KUY ​. [1]

Aralkylamine N-acetyltransferase has also been crystallized in complex with 14-3-3ζ from the 14-3-3 protein family, with the PDB accession code 1IB1 ​. [11]

The GNAT superfamily

Aralkylamine N-acetyltransferase belongs to the GCN5-related N-acetyltransferase (GNAT) superfamily which consists 10,000 acetyltransferases, named so because of their sequence homology to a class of eukaryotic transcription factors, therein the yeast GCN5. Other well-studied members of the superfamily are glucosamine-6-phosphate N-acetyltransferase and histone acetyltransferases.

All members of this superfamily has a structurally conserved fold consisting of an N-terminal strand followed by two helices, three antiparallel β-strands, followed by a ‘‘signature’’ central helix, a fifth β-strand, a fourth α-helix and a final β-strand. These elements are nearly universally conserved in spite of poor pairwise identity in sequence alignments. [12]

Regulation

Regulation of AANAT varies between species. In some, AANAT levels oscillate dramatically between light and dark periods, and thus control melatonin synthesis. In others, rhythm is regulated primarily on the protein level. [13] One example is in rodents, where AANAT mRNA levels increase more than 100-fold in dark periods. In other species, cyclic AMP plays an important part in inhibition of proteolytic degradation of AANAT, elevating protein levels at night. Experiments using human AANAT expressed in a 1E7 cell line show an ~8-fold increase in enzyme activity upon exposure to forskolin. [14]

Dynamic degradation of AANAT mRNA has proven essential to the circadian action of the enzyme. The 3’UTR sequences have importance with regards to the rhythmic degradation of AANAT mRNA in some species. In rodents, various hnRNPs maintain dynamic degradation of AANAT mRNA. In other species, such as ungulates and primates, the stable AANAT mRNAs with a shorter 3’UTR is suspected not to be under control of the hnRNPs that bind and direct degradation of AANAT mRNA in rodents. [15]

Exposure to light induces signals to travel from retinal cells, ultimately causing a drop in norepinephrine stimulation of the pineal gland. This, in turn, leads to a signaling cascade, resulting in Protein Kinase A phosphorylation of two key Ser and Thr residues of serotonin N-acetyltransferase. Phosphorylation of these residues causes changes in catalytic activity through recruitment and interaction with 14-3-3 proteins, specifically 14-3-3ζ. [16]

Another protein which interacts and regulates AANAT activity is protein kinase C. Protein kinase C acts, like protein kinase A, on threonine and serine residues, enhancing the stability and enzymatic activity of AANAT. [17]

Inhibition of the acetyl-CoA-binding to the catalytic site through the formation and cleavage of intramolecular disulfide bonds has been suggested to be a mechanism of regulation. Formation of a disulfide bond between two cystein residues within the protein closes the hydrophobic funnel of the catalytic site, and thus acts as an on/off switch for catalytic activity. It is not yet certain if this mechanism is present in in vivo cells through the regulation of intracellular redox conditions, but it is suggested that glutathione (GSH) could be an in vivo regulator of the formation and cleavage of these disulfide bonds. [18]

AANAT inhibitors and clinical relevance

Inhibitors of AANAT may eventually lead to development of a drug that would be useful in circadian biology research and in the treatment of sleep and mood disorders. Synthetic inhibitors of the enzyme have been discovered. [19] [20] [21] However, no AANAT inhibitor with potent in vivo activity has been reported. [22] Up to now, five classes of AANAT inhibitors have been described in the literature. [6] Below are the five classes:

Melatonin derivatives

Since it was reported that melatonin is a competitive inhibitor of AANAT, this neurotransmitter seems to exert an autoregulatory control on its own biosynthesis. Thus, loose structural analogues of the indolamine hormone were evaluated on AANAT, and moderate inhibitors were discovered. [23]

Peptidic inhibitors

Peptide combinatorial libraries of tri-, tetra-, and pentapeptides with various amino acid compositions were screened as potential sources of inhibitors, to see if it serves as either pure or mixed competitive inhibitor for the hAANAT enzyme. Molecular modeling and structure-activity relationship studies made it possible to pinpoint the amino acid residue of the pentapeptide inhibitor S 34461 that interacts with the cosubstrate-binding site. [24]

Bisubstrate analogs

It is suggested that AANAT catalyzes the transfer of an acetyl group from acetyl-CoA to serotonin, with the involvement of an intermediate ternary complex, to produce N-acetylserotonin. Based on this mechanism, it might be expected that a bisubstrate analog inhibitor, derived from the tethering of indole and CoASH parts, could potentially mimic the ternary complex and exert strong inhibition of AANAT. [25] The first bisubstrate analog (1), which links tryptamine and CoA via an acetyl bridge, was synthesized by Khalil and Cole, and shown to be a very potent and specific AANAT inhibitor. [26]

N-Haloacetylated derivatives

AANAT has shown that it also has a secondary alkyltransferase activity as well as acetyltransferase activity. [27] N-Haloacetyltryptamines were developed and serve as substrates of AANAT alkyltransferase and are also potent (low micromolar) in vitro inhibitors against AANAT acetyltransferase activity. AANAT catalyzes reaction between N-bromoacetyltryptamine (BAT) and reduced CoA, resulting a tight-binding bisubstrate analog inhibitor. [27] [28] The first synthesized cell-permeable inhibitor of AANAT N-bromoacetyltryptamine was studied further on melatonin secretion from rat and pig pineal glands. [29] New N-halogenoacetyl derivatives leading to a strong in situ inhibition of AANAT. The concept behind the mechanism of action of these precursors was studied by following the biosynthesis of the inhibitor from tritiated-BAT in a living cell. [20]

Rhodanine-based compounds

The first druglike and selective inhibitors of AANAT has been identified. Lawrence M. Szewczuk et al. have virtually screened more than a million compounds by 3D high-throughput docking into the active site of X-ray structure for AANAT, and then tested 241 compounds as inhibitors. One compound class which containing a rhodanine scaffold has shown low micromolar competitive inhibition against acetyl-CoA and proved to be effective in blocking melatonin production in pineal cells. [19]

The recent study about inhibitor of AANAT has described the discovery of a new class of nonpeptidic AANAT inhibitors based on a 2,2′-bithienyl scaffold. [22]

See also

Related Research Articles

<span class="mw-page-title-main">Melatonin</span> Hormone released by the pineal gland

Melatonin is a natural compound, specifically an indoleamine, produced by and found in different organisms including bacteria and eukaryotes. It was discovered by Aaron B. Lerner and colleagues in 1958 as a substance of the pineal gland from cow that could induce skin lightening in common frogs. It was subsequently discovered as a hormone released in the brain at night which controls the sleep–wake cycle in vertebrates.

<span class="mw-page-title-main">Histone acetyltransferase</span> Enzymes that catalyze acyl group transfer from acetyl-CoA to histones

Histone acetyltransferases (HATs) are enzymes that acetylate conserved lysine amino acids on histone proteins by transferring an acetyl group from acetyl-CoA to form ε-N-acetyllysine. DNA is wrapped around histones, and, by transferring an acetyl group to the histones, genes can be turned on and off. In general, histone acetylation increases gene expression.

<span class="mw-page-title-main">Pinealocyte</span> Main cells contained in the pineal gland

Pinealocytes are the main cells contained in the pineal gland, located behind the third ventricle and between the two hemispheres of the brain. The primary function of the pinealocytes is the secretion of the hormone melatonin, important in the regulation of circadian rhythms. In humans, the suprachiasmatic nucleus of the hypothalamus communicates the message of darkness to the pinealocytes, and as a result, controls the day and night cycle. It has been suggested that pinealocytes are derived from photoreceptor cells. Research has also shown the decline in the number of pinealocytes by way of apoptosis as the age of the organism increases. There are two different types of pinealocytes, type I and type II, which have been classified based on certain properties including shape, presence or absence of infolding of the nuclear envelope, and composition of the cytoplasm.

<span class="mw-page-title-main">Catalytic triad</span> Set of three coordinated amino acids

A catalytic triad is a set of three coordinated amino acids that can be found in the active site of some enzymes. Catalytic triads are most commonly found in hydrolase and transferase enzymes. An acid-base-nucleophile triad is a common motif for generating a nucleophilic residue for covalent catalysis. The residues form a charge-relay network to polarise and activate the nucleophile, which attacks the substrate, forming a covalent intermediate which is then hydrolysed to release the product and regenerate free enzyme. The nucleophile is most commonly a serine or cysteine amino acid, but occasionally threonine or even selenocysteine. The 3D structure of the enzyme brings together the triad residues in a precise orientation, even though they may be far apart in the sequence.

<span class="mw-page-title-main">N-acetyltransferase</span>

N-acetyltransferase (NAT) is an enzyme that catalyzes the transfer of acetyl groups from acetyl-CoA to arylamines, arylhydroxylamines and arylhydrazines. They have wide specificity for aromatic amines, particularly serotonin, and can also catalyze acetyl transfer between arylamines without CoA. N-acetyltransferases are cytosolic enzymes found in the liver and many tissues of most mammalian species, except the dog and fox, which cannot acetylate xenobiotics.

<span class="mw-page-title-main">Hexosaminidase</span> Class of enzymes

Hexosaminidase is an enzyme involved in the hydrolysis of terminal N-acetyl-D-hexosamine residues in N-acetyl-β-D-hexosaminides.

<span class="mw-page-title-main">Serine/threonine-specific protein kinase</span> Class of protein kinase enzymes

A serine/threonine protein kinase is a kinase enzyme, in particular a protein kinase, that phosphorylates the OH group of the amino-acid residues serine or threonine, which have similar side chains. At least 350 of the 500+ human protein kinases are serine/threonine kinases (STK).

<span class="mw-page-title-main">Tryptophan hydroxylase</span> Class of enzymes

Tryptophan hydroxylase (TPH) is an enzyme (EC 1.14.16.4) involved in the synthesis of the neurotransmitter serotonin. Tyrosine hydroxylase, phenylalanine hydroxylase, and tryptophan hydroxylase together constitute the family of biopterin-dependent aromatic amino acid hydroxylases. TPH catalyzes the following chemical reaction

<span class="mw-page-title-main">Long-chain-fatty-acid—CoA ligase</span> Class of enzymes

The long chain fatty acyl-CoA ligase is an enzyme of the ligase family that activates the oxidation of complex fatty acids. Long chain fatty acyl-CoA synthetase catalyzes the formation of fatty acyl-CoA by a two-step process proceeding through an adenylated intermediate. The enzyme catalyzes the following reaction,

<span class="mw-page-title-main">Carnitine palmitoyltransferase I</span> Protein-coding gene in the species Homo sapiens

Carnitine palmitoyltransferase I (CPT1) also known as carnitine acyltransferase I, CPTI, CAT1, CoA:carnitine acyl transferase (CCAT), or palmitoylCoA transferase I, is a mitochondrial enzyme responsible for the formation of acyl carnitines by catalyzing the transfer of the acyl group of a long-chain fatty acyl-CoA from coenzyme A to l-carnitine. The product is often Palmitoylcarnitine, but other fatty acids may also be substrates. It is part of a family of enzymes called carnitine acyltransferases. This "preparation" allows for subsequent movement of the acyl carnitine from the cytosol into the intermembrane space of mitochondria.

<span class="mw-page-title-main">Acetylserotonin O-methyltransferase</span> Mammalian protein found in humans

N-Acetylserotonin O-methyltransferase, also known as ASMT, is an enzyme which catalyzes the final reaction in melatonin biosynthesis: converting Normelatonin to melatonin. This reaction is embedded in the more general tryptophan metabolism pathway. The enzyme also catalyzes a second reaction in tryptophan metabolism: the conversion of 5-hydroxy-indoleacetate to 5-methoxy-indoleacetate. The other enzyme which catalyzes this reaction is n-acetylserotonin-o-methyltransferase-like-protein.

<i>N</i>-Acetylserotonin Chemical compound

N-Acetylserotonin (NAS), also known as normelatonin, is a naturally occurring chemical intermediate in the endogenous production of melatonin from serotonin. It also has biological activity in its own right, including acting as a melatonin receptor agonist, an agonist of the TrkB, and having antioxidant effects.

<span class="mw-page-title-main">MMP7</span> Protein-coding gene in humans

Matrilysin also known as matrix metalloproteinase-7 (MMP-7), pump-1 protease (PUMP-1), or uterine metalloproteinase is an enzyme in humans that is encoded by the MMP7 gene. The enzyme has also been known as matrin, putative metalloproteinase-1, matrix metalloproteinase pump 1, PUMP-1 proteinase, PUMP, metalloproteinase pump-1, putative metalloproteinase, MMP). Human MMP-7 has a molecular weight around 30 kDa.

In enzymology, an alpha-tubulin N-acetyltransferase is an enzyme which is encoded by the ATAT1 gene.

<span class="mw-page-title-main">Carnitine O-acetyltransferase</span> Enzyme

Carnitine O-acetyltransferase also called carnitine acetyltransferase is an enzyme that encoded by the CRAT gene that catalyzes the chemical reaction

<span class="mw-page-title-main">Carnitine O-octanoyltransferase</span>

Carnitine O-octanoyltransferase is a member of the transferase family, more specifically a carnitine acyltransferase, a type of enzyme which catalyzes the transfer of acyl groups from acyl-CoAs to carnitine, generating CoA and an acyl-carnitine. The systematic name of this enzyme is octanoyl-CoA:L-carnitine O-octanoyltransferase. Other names in common use include medium-chain/long-chain carnitine acyltransferase, carnitine medium-chain acyltransferase, easily solubilized mitochondrial carnitine palmitoyltransferase, and overt mitochondrial carnitine palmitoyltransferase. Specifically, CROT catalyzes the chemical reaction:

<span class="mw-page-title-main">Glucosamine-phosphate N-acetyltransferase</span>

In enzymology, glucosamine-phosphate N-acetyltransferase (GNA) is an enzyme that catalyzes the transfer of an acetyl group from acetyl-CoA to the primary amine in glucosamide-6-phosphate, generating a free CoA and N-acetyl-D-glucosamine-6-phosphate.

<span class="mw-page-title-main">Serine O-acetyltransferase</span>

In enzymology, a serine O-acetyltransferase is an enzyme that catalyzes the chemical reaction

Protein acetylation are acetylation reactions that occur within living cells as drug metabolism, by enzymes in the liver and other organs. Pharmaceuticals frequently employ acetylation to enable such esters to cross the blood–brain barrier, where they are deacetylated by enzymes (carboxylesterases) in a manner similar to acetylcholine. Examples of acetylated pharmaceuticals are diacetylmorphine (heroin), acetylsalicylic acid (aspirin), THC-O-acetate, and diacerein. Conversely, drugs such as isoniazid are acetylated within the liver during drug metabolism. A drug that depends on such metabolic transformations in order to act is termed a prodrug.

<span class="mw-page-title-main">Ghrelin O-acyltransferase</span> Protein-coding gene in the species Homo sapiens

Ghrelin O-acyltransferase also known as membrane bound O-acyltransferase domain containing 4 is an enzyme that in humans is encoded by the MBOAT4 gene. It is homologous to other membrane-bound O-acyltransferases. It is a polytopic membrane protein what takes part in lipid signaling reactions. It is the only known enzyme that catalyzes the acylation of ghrelin through the transfer of n-octanoic acid to ghrelin Ser3. Ghrelin O-acyltransferase function is essential in regulation of appetite and the release of growth hormone. Ghrelin O-acyltransferase is a target for scientific research due to promising applications in the treatment of diabetes, eating disorders, and metabolic diseases.

References

  1. 1 2 3 4 PDB: 1KUX ​; Wolf E, De Angelis J, Khalil EM, Cole PA, Burley SK (March 2002). "X-ray crystallographic studies of serotonin N-acetyltransferase catalysis and inhibition". J. Mol. Biol. 317 (2): 215–24. doi:10.1006/jmbi.2001.5371. PMID   11902838.
  2. 1 2 3 "Entrez Gene: arylalkylamine N-acetyltransferase".
  3. 1 2 Coon SL, Mazuruk K, Bernard M, Roseboom PH, Klein DC, Rodriguez IR (May 1996). "The human serotonin N-acetyltransferase (EC 2.3.1.87) gene (AANAT): structure, chromosomal localization, and tissue expression". Genomics. 34 (1): 76–84. doi:10.1006/geno.1996.0243. PMID   8661026.
  4. ↑ "IUBMB Enzyme Nomenclature EC 2.3.1.87". Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Retrieved 15 November 2014.
  5. ↑ "EC 2.3.1.87 - aralkylamine N-acetyltransferase". BRENDA. Technische Universität Braunschweig. July 2014. Retrieved 10 November 2014.
  6. 1 2 Zheng W, Cole PA (June 2002). "Serotonin N-acetyltransferase: mechanism and inhibition". Curr. Med. Chem. 9 (12): 1187–99. doi:10.2174/0929867023370013. PMID   12052171.
  7. ↑ J. De Angelis; J. Gastel; D. C. Klein; P. A. Cole (January 1998). "Kinetic analysis of the catalytic mechanism of serotonin N-acetyltransferase (EC 2.3.1.87)". The Journal of Biological Chemistry . 273 (5): 3045–3050. doi: 10.1074/jbc.273.5.3045 . PMID   9446620.
  8. ↑ Hickman AB, Namboodiri MA, Klein DC, Dyda F (April 1999). "The structural basis of ordered substrate binding by serotonin N-acetyltransferase: enzyme complex at 1.8 A resolution with a bisubstrate analog". Cell. 97 (3): 361–9. doi: 10.1016/S0092-8674(00)80745-X . PMID   10319816. S2CID   18272015.
  9. ↑ Hickman AB, Klein DC, Dyda F (January 1999). "Melatonin biosynthesis: the structure of serotonin N-acetyltransferase at 2.5 A resolution suggests a catalytic mechanism". Mol. Cell. 3 (1): 23–32. doi: 10.1016/S1097-2765(00)80171-9 . PMID   10024876.
  10. ↑ Scheibner KA, De Angelis J, Burley SK, Cole PA (May 2002). "Investigation of the roles of catalytic residues in serotonin N-acetyltransferase". J. Biol. Chem. 277 (20): 18118–26. doi: 10.1074/jbc.M200595200 . PMID   11884405.
  11. ↑ Obsil T, Ghirlando R, Klein DC, Ganguly S, Dyda F (April 2001). "Crystal structure of the 14-3-3zeta:serotonin N-acetyltransferase complex. a role for scaffolding in enzyme regulation". Cell. 105 (2): 257–67. doi: 10.1016/S0092-8674(01)00316-6 . PMID   11336675. S2CID   9564413.
  12. ↑ Matthew W. Vetting; Luiz Pedro S. de Carvalho; Michael Yu; Subray S. Hegde; Sophie Magnet; Steven L. Roderick & John S. Blanchard (January 2005). "Structure and functions of the GNAT superfamily of acetyltransferases". Archives of Biochemistry and Biophysics. 433 (1): 212–226. doi:10.1016/j.abb.2004.09.003. PMID   15581578.
  13. ↑ Klein, D. C.; Coon, S. L.; Roseboom, P. H.; Weller, J. L.; Bernard, M.; Gastel, J. A.; Zatz, M.; Iuvone, P. M.; Rodriguez, I. R.; Bégay, V.; Falcón, J.; Cahill, G. M.; Cassone, V. M.; Baler, R. (1997). "The melatonin rhythm-generating enzyme: Molecular regulation of serotonin N-acetyltransferase in the pineal gland". Recent Progress in Hormone Research. 52: 307–357, discussion 357–8. PMID   9238858.
  14. ↑ Coon SL, Weller JL, Korf HW, Namboodiri MA, Rollag M, Klein DC (June 2001). "cAmp regulation of arylalkylamine N-acetyltransferase (AANAT, EC 2.3.1.87): a new cell line (1E7) provides evidence of intracellular AANAT activation". J. Biol. Chem. 276 (26): 24097–107. doi: 10.1074/jbc.M011298200 . PMID   11313340.
  15. ↑ Kim TD, Kim JS, Kim JH, Myung J, Chae HD, Woo KC, Jang SK, Koh DS, Kim KT (April 2005). "Rhythmic serotonin N-acetyltransferase mRNA degradation is essential for the maintenance of its circadian oscillation". Mol. Cell. Biol. 25 (8): 3232–46. doi:10.1128/MCB.25.8.3232-3246.2005. PMC   1069600 . PMID   15798208.
  16. ↑ Szewczuk LM, Tarrant MK, Sample V, Drury WJ, Zhang J, Cole PA (September 2008). "Analysis of serotonin N-acetyltransferase regulation in vitro and in live cells using protein semisynthesis". Biochemistry. 47 (39): 10407–19. doi:10.1021/bi801189d. PMC   2682328 . PMID   18771288.
  17. ↑ Choi BH, Chae HD, Park TJ, Oh J, Lim J, Kang SS, Ha H, Kim KT (July 2004). "Protein kinase C regulates the activity and stability of serotonin N-acetyltransferase". J. Neurochem. 90 (2): 442–54. doi:10.1111/j.1471-4159.2004.02495.x. PMID   15228600. S2CID   42638894.
  18. ↑ Tsuboi S, Kotani Y, Ogawa K, Hatanaka T, Yatsushiro S, Otsuka M, Moriyama Y (November 2002). "An intramolecular disulfide bridge as a catalytic switch for serotonin N-acetyltransferase". J. Biol. Chem. 277 (46): 44229–35. doi: 10.1074/jbc.M203305200 . PMID   12215431.
  19. 1 2 Lawrence M. Szewczuk; S. Adrian Saldanha; Surajit Ganguly; Erin M. Bowers; Margarita Javoroncov; Balasubramanyam Karanam; Jeffrey C. Culhane; Marc A. Holbert; David C. Klein; Ruben Abagyan; Philip A. Cole (November 2007). "De novo discovery of serotonin N-acetyltransferase inhibitors". Journal of Medicinal Chemistry. 50 (22): 5330–5338. doi:10.1021/jm0706463. PMC   2531295 . PMID   17924613.
  20. 1 2 Ferry G, Ubeaud C, Mozo J, Péan C, Hennig P, Rodriguez M, Scoul C, Bonnaud A, Nosjean O, Galizzi JP, Delagrange P, Renard P, Volland JP, Yous S, Lesieur D, Boutin JA (January 2004). "New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors". Eur. J. Biochem. 271 (2): 418–28. doi: 10.1046/j.1432-1033.2003.03942.x . PMID   14717709.
  21. ↑ Zheng W, Cole PA (October 2003). "Novel bisubstrate analog inhibitors of serotonin N-acetyltransferase: the importance of being neutral". Bioorg. Chem. 31 (5): 398–411. doi:10.1016/S0045-2068(03)00081-6. PMID   12941292.
  22. 1 2 Lepailleur A, Lemaître S, Feng X, Sopkova-de Oliveira Santos J, Delagrange P, Boutin J, Renard P, Bureau R, Rault S (March 2010). "Receptor- and ligand-based study on novel 2,2'-bithienyl derivatives as non-peptidic AANAT inhibitors". J Chem Inf Model. 50 (3): 446–60. doi:10.1021/ci9004805. PMID   20196559.
  23. ↑ Shen S, Brémont B, Serraz I, Andrieux J, Poncet A, Mathé-Allainmat M, Chanut E, Trouvin JH, Langlois M (June 1996). "Structure-activity relationships for substrates and inhibitors of pineal 5-hydroxytryptamine-N-acetyltransferase: preliminary studies". Eur. J. Pharmacol. 307 (2): 133–40. doi:10.1016/0014-2999(96)00228-2. PMID   8832214.
  24. ↑ Ferry G, Loynel A, Kucharczyk N, Bertin S, Rodriguez M, Delagrange P, Galizzi JP, Jacoby E, Volland JP, Lesieur D, Renard P, Canet E, Fauchère JL, Boutin JA (March 2000). "Substrate specificity and inhibition studies of human serotonin N-acetyltransferase". J. Biol. Chem. 275 (12): 8794–805. doi: 10.1074/jbc.275.12.8794 . PMID   10722724.
  25. ↑ Page, A.I. (1990). "Enzyme inhibition". Comprehensive Medicinal Chemistry. 2: 61–87.
  26. ↑ Khalil, Ehab M.; Philip A. Cole (6 June 1998). "A Potent Inhibitor of the Melatonin Rhythm Enzyme". J. Am. Chem. Soc. 120 (24): 6195–6196. doi:10.1021/ja981365a.
  27. 1 2 Khalil EM, De Angelis J, Ishii M, Cole PA (October 1999). "Mechanism-based inhibition of the melatonin rhythm enzyme: pharmacologic exploitation of active site functional plasticity". Proceedings of the National Academy of Sciences of the United States of America. 96 (22): 12418–12423. Bibcode:1999PNAS...9612418K. doi: 10.1073/pnas.96.22.12418 . PMC   22936 . PMID   10535937.
  28. ↑ Zheng W, Scheibner KA, Ho AK, Cole PA (April 2001). "Mechanistic studies on the alkyltransferase activity of serotonin N-acetyltransferase". Chemistry & Biology. 8 (4): 379–389. doi: 10.1016/s1074-5521(01)00020-5 . PMID   11325593.
  29. ↑ Lewczuk B, Zheng W, Prusik M, Cole PA, Przybylska-Gornowicz B (October 2005). "N-bromoacetyltryptamine strongly and reversibly inhibits in vitro melatonin secretion from mammalian pinealocytes". Neuroendocrinology Letters. 26 (5): 581–592. PMID   16264397.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.